Synthetic peptides derived from vitronectin and pharmaceutical c

Details Synthetic peptides derived from vitronectin and pharmaceutical c Synthetic peptides derived from vitronectin and pharmaceutical c

1993-07-29

1996-02-13

Warden, Jill

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 11, 514 13, 530317, 530324, 530326, A61K 3800, C07K 500, C07K 700, C07K 1700

Patent

active

054911290

ABSTRACT:
The invention relates to synthetic peptides derived from the K.sup.348 -A.sup.380 (8-40 of SEQ ID NO:1) sequence of the vitronectin molecule. The peptides modulate the biological activities of plasminogen activator inhibitor-1 (PAI-1) and are useful as active ingredients of pharmaceutical compositions for the treatment of disorders such as bleeding disorders, acute myocardial infarction, deep vein thrombosis, pulmonary embolism, disseminated intravascular coagulation, tumor cell invasion and metastasis, inflammation, liver diseases, bacterial blood infections, pregnancy toxicosis, and pathological conditions associated with the control of angiogenesis, or with nerve regeneration, or with excessive tPA-mediated proteolysis.

REFERENCES:
Reilly et al, Fibrinolysis vol. 6 pp. 167-171 & (Jul. 1992).
Jenne et al, Biochem. vol. 26 pp. 6735-6742 (1987).
Suzuki et al, EMBO J. vol. 4 pp. 2519-2524 (1985).
De Boer et al., Binding of Vitronectin-Thrombin-Antithrombin III Complex to Human Endothelial Cells Is Mediated by the Heparin Binding Site of Vitronectin, The Journal of Biological Chemistry, vol. 267, No. 4, pp. 2264-2268, 1992.
Cajot et al., Plasminogen-Activator Inhibitor Type 1 Is A Potent Natural Inhibitor of Extracellular Matrix Degradation by Fibrosarcoma and Colon Carcinoma Cells, Proc. Natl. Acad. Sci. USA, vol. 87, pp. 6939-6943, Sep. 1990.
Chain et al., The Phosphorylation of the Two-Chain Form of Vitronectin by Protein Kinase A is Heparin Dependent, FEBS, vol. 269 No. 1, pp. 221-225, Aug. 1990.
Chain, et al., Endogenous Cleavage of the Arg-379-Ala-380 Bond in Vitronectin Results in a Distinct Conformational Change Which `Buries` Ser-378, Its Site of Phosphorylation by Protein Kinase A, Biochem. J., vol. 274, pp. 387-395, 1991.
Chain et al., Plasmin Cleavage of Vitronectin, FEBS, vol. 285, No. 2, pp. 251-256, Jul. 1991.
Chmielewska, et al., Evidence For A Rapid Inhibitor To Tissue Plasminogen Activator In Plasma, Thrombosis Research, vol. 31, pp. 427-436, 1983.
Collen et al., Identification and Some Properties of a New Fast-Reacting Plasmin Inhibitor in Human Plasma, Eur. J. Biochem., vol. 69, pp. 209-216, 1976.
Dalhback et al., Characterization of Human S Protein, An Inhibitor of the Membrane Attack Complex of Complement. Demonstration of a Free Reactive Thiol Group, Biochemistry, vol. 24, pp. 2368-2374, 1985.
Dano et al., Plasminogen Activators, Tissue Degradation, and Cancer, Advances in Cancer Research, vol. 44, pp. 139-166, 1985.
Declerck et al., Purification and Characterization of a Plasminogen Activator Inhibitor 1 Binding Protein From Human Plasma, The Journal of Biological Chemistry, vol. 263, No. 30, pp. 15454-15461, 25 Oct. 1988.
Jenne et al., Molecular Cloning of S-Protein, A Link Between Complement, Coagulation and Cell-Substrate Adhesion, The EMBO Journal, vol. 4, No. 12, pp. 3153-3157, 1985.
Katagiri et al., Bovine Endothelial Cell Plasminogen Activator Inhibitor, Eur. J. Biochem., vol. 176, pp. 81-87, 1988.
Korc-Grodzicki et al., Platelet Stimulation Releases A cAMP-Dependent Protein Kinase That Specifically Phosphorylates A Plasma Protein, Proc. Natl. Acad. Sci. USA, vo. 85, pp. 7541-7545, Oct. 1988.
Korc-Grodzicki et al., Vitronectin Is Phosphorylated By a cAMP-Dependent Protein Kinase Released By Activation Of Human Platelets With Thrombin, Biochemical and Biophysical Research Communications, vol. 157, No. 3, pp. 1131-1138, 30 Dec. 1988.
Korc-Grodzicki et al., An Enzymatic Assay for Vitronectin Based on Its Selective Phophorylation by Protein Kinase A, Analytical Biochemistry, vol. 188, pp. 288-294, 1990.
Kost et al., Mapping of Binding Sites for Heparin, Plasminogen Activator Inhibitor-1, and Plasminogen to Vitronectin's Heparin-Binding Region Reveals a Novel Vitronectin-Dependent Feedback Mechanism for the Control of Plasmin Formation, The Journal of Biological Chemistry, vol. 267, No. 17, pp. 12098-12105, 1992.
Mignatti et al., In Vitro Angiogenesis on the Human Amniotic Membrane: Requirement for Basic Fibroblast Growth Factor--Induced Proteinases, The Journal of Cell Biology, vol. 108, pp. 671-682, Feb. 1989.
Mimuro et al., Purification of a Protein from Bovine Plasma That Binds to Type 1 Plasminogen Activator Inhibitor and Prevents Its Interaction with Extracellular Matrix, The Journal of Biological Chemistry, vol. 264, No. 2, pp. 936-939, 15 Jan. 1989.
Pollanen et al., Ultrasonic Localization of Plasma Membrane-Associated Urokinase-Type Plasminogen Activator at Focal Contacts, The Journal of Cell Biology, vol. 106, pp. 87-95, Jan. 1988.
Preissner et al., Structural Requirements for the Extracellular Interaction of Plasminogen Activator Inhibitor 1 with Endothelial Cell Matrix-Associated Vitronectin, The Journal of Cell Biology, vol. 265, No. 30, pp. 18490-18498, 25 Oct. 1990.
Rylatt et al., An Immunoassay For Human D Dimer Using Monoclonal Antibodies, Thrombosis Research, vol. 31, pp. 767-778, 1983.
Salonen et al., Interaction of Plasminogen Activator Inhibitor (PAI-1) with Vitronectin, The Journal of Biological Chemistry, vol. 264, No. 11, pp. 6339-6343, 14 Apr. 1989.
Sprengers et al., Plasminogen Activator Inhibitors, Blood, vol. 69, No. 2, pp. 381-387, Feb. 1987.

Affiliated with

Also associated with

Rating

Synthetic peptides derived from vitronectin and pharmaceutical c does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Synthetic peptides derived from vitronectin and pharmaceutical c, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synthetic peptides derived from vitronectin and pharmaceutical c will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-240598